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Background: In the past few years, the number of clinical trials has increased rapidly in East Asia, especially for
gastric and hepatobiliary cancer that are prevalent in Asian populations. However, the actual degree of
understanding or perceptions of clinical trials by cancer patients in East Asian countries have seldom been studied.
Methods: Between July 1st and November 30th of 2011, we conducted a prospective study to survey cancer
patients regarding their awareness of, and willingness to participate in, a clinical trial. Patients with gastrointestinal/
hepatobiliary cancer who visited the Hematology-Oncology outpatient clinic at Samsung Medical Center (SMC)
were enrolled. A total of 21 questions were asked including four questions which used the Visual analogue scale
(VAS) score.
Results: In this survey study, 1,000 patients were asked to participate and 675 patients consented to participate
(67.5%). The awareness of clinical trials was substantially higher in patients who had a higher level of education
(p<0.001), were married (p=0.004), and had a higher economic status (p=0.001). However, the willingness to
participate in a clinical trial was not affected by the level of education or economic status of patients. The most
influential factors for patient willingness to participate were a physician recommendation (n=181, 26.8%), limited
treatment options (n=178, 26.4%), and expectations of effectiveness of new anti-cancer drugs (n=142, 21.0%).
Patients with previous experience in clinical trials had a greater willingness to participate in clinical trials compared
to patients without previous experience (p<0.001).
Conclusions: This large patient cohort survey study showed that Korean cancer patients are more aware of clinical
trials, but awareness did not translate into willingness to participate.
Keywords: Cancer clinical trial, Survey, Awareness and willingness to participateBackground
Oncology is one of the most rapidly developing fields in
medicine and a greater understanding of tumours at the
molecular level has resulted in the development of many
novel therapeutic agents. Cancer clinical trials are
needed to evaluate the efficacy and toxicity of these
newly-developed agents and have become an essential
component of oncology [1,2]. Besides the design of the
trial and the efficacy of the drug, the key success factor* Correspondence: jyunlee@skku.edu; psy27hmo@samsung.com
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reproduction in any medium, provided the orto conducting an effective clinical trial is an understand-
ing and awareness of clinical trials by cancer patients.
Patient attitude towards a clinical trial could greatly in-
fluence patient recruitment and retention. Although
general attitudes towards clinical trials are positive in
Western Countries, the number of patients actually en-
rolled in clinical trials tends to be low [3-7]. The known
barriers to successful clinical trials include changes in
hospital administrative systems, fewer eligible patients
than anticipated (inaccurate feasibility), problems inher-
ent in certain types of trials or methodology (e.g. placebo
control), no treatment arms (supportive care only), and
difficulties in describing randomization [8-10]. One of
the major patient-related factors affecting the success of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ness by the patients themselves, which may impede pa-
tient accrual. Hence, it is necessary to understand the
perception of clinical trials by cancer patients.
Previous studies have used questionnaires to examine
patient expectation and understanding of clinical trials,
to elucidate existing barriers and to improve the pro-
cesses of clinical trials [11-14]. The National Cancer
Institute (NCI) estimated that less than 5% of newly
diagnosed adult cancer patients are enrolled in clinical
trials in the United States [1]. In Asia, even though the
number of clinical trials has increased rapidly in the past
decade, especially for cancer types prevalent in the Asian
population, the awareness, understanding and/or willing-
ness to participate has scarcely been reported. In fact,
Korea leads Asia in patient recruitment for cancer trials
and is 10th in the world [15]. Owing to a relatively short
history of cancer clinical trials and cultural differences in
the doctor-patient relationship, Western data on patient
attitude may not be directly applicable to such Eastern
populations. In addition, cancer type could also affect
the perception of and participation in a clinical trial, but
few studies have addressed these questions [16].
The aim of this study was therefore to survey and
analyze the degree of understanding and perceptions of
clinical trials in Korea.
Methods
Data collection
From July 1st to November 30th of 2011, we surveyed can-
cer patients who were diagnosed with gastrointestinal
cancer (including gastric, colorectal, esophageal, small in-
testinal, hepatobiliary, and pancreatic cancer) at Samsung
Medical Center in Korea and who visited the outpatient
clinic at the Division of Hematology-Oncology. The eligi-
bility criteria were: 1) aged >19 years; 2) histologically
confirmed gastrointestinal or hepatobiliary-pancreatic can-
cer; and 3) signed informed consent.
One well-trained research nurse explained the purpose
of the survey and received written informed consent
from all participants before they were enrolled in the
study. All participants completed the questionnaire by
themselves. With the agreement of the participants,
clinical information of each patient was collected from
medical records. This study was approved by the Institu-
tional Review Board of the Association for the Accredi-
tation of Human Research Protection Program,
approved by Samsung Medical Center. The study was
carried out in accordance with the tenets of the Declar-
ation of Helsinki.
Questionnaire
The questionnaire consisted of 21 questions based on an
Index of Clinical Trial Understanding [17], and includedquestions that used a Visual analogue scale (VAS) score,
as well as single- and multiple-choice questions. The
survey was developed in collaboration with the Biostatis-
tics Core at Samsung Medical Center. A VAS between 0
and 10 was used in the survey to evaluate the level of
awareness of clinical trials and participation in them. A
VAS score of zero indicated ‘never’ and 10 indicated ‘ab-
solute’. Eight of the questions concerned demographics
such as age, sex, travel distance from the hospital, level
of education, residence, marital status, economic status,
and religion. Eight more questions asked about cancer
clinical trial understanding (awareness) based on an
Index of Clinical Trial Understanding [17], and the
remaining five questions were about willingness to par-
ticipate in clinical trials (Additional file 1).
Statistical analyses
The Kruskal-Wallis rank sum test and the Mann–Whitney
test were used in the analysis of awareness and willingness
according to patient characteristics. Fisher's Exact Test for
Count Data was used, depending on the presence or
absence of clinical trial experience. The VAS score with
multiple factors (answers for single-choice or multiple-
choice questions) was analyzed by Kruskal-Wallis rank
sum test or Kruskal-Wallis chi-squared test. VAS scores of
both groups were analyzed by Spearman correlation ana-
lysis. A biostatistician was consulted for all statistical
designs and analyses and all tests were considered statisti-
cally significant at a p< 0.05.
Results
Patient cohort
From July 1st to November 30th of 2011, a total of 1,000
patients were asked to participate in the study, and 675
patients (67.5%) agreed to complete the questionnaire.
Patients who were diagnosed with gastrointestinal or
hepatobiliary-pancreatic cancer (gastric, colorectal, esopha-
geal, small intestinal, hepatobiliary, pancreatic cancer) at
Samsung Medical Center in Korea were enrolled in the
study. Table 1 shows the participant characteristics at
baseline. The age of the participants ranged widely from
31 to 86 years, with a median age of 60 years. More
patients were male than female (n=438, 64.9% vs. n=237,
35.1%). High school was the most frequent level of educa-
tion (47.0%) and most participants were married (90.8%).
Colorectal cancer was the most common cancer type
(n=341) followed by gastric cancer (n=191), hepatobiliary
cancer (n=57), pancreatic cancer (n=51), esophageal can-
cer (n=25), and small bowel cancer (n=10). In terms of the
disease status, 254 patients (37.7%) were in first-line
palliative chemotherapy, 250 (37.0%) were in neoadjuvant
or adjuvant chemotherapy and the remaining patients
(N=168, 24.9%) were in more than second-line chemo-
therapy. A total of 127 participants (18.8%) had a prior




Age Median(years) 60 ± 10
Sex Male 438 64.9
Female 237 35.1
Travel time (to Hospital
from home)
<2 hours 363 53.8
≥2 hours 312 46.2






Education level ≤Middle school 154 22.8
High school graduate 317 47.0
≥College graduate 204 30.2





≥5.000.000 won* 89 13.2
2.000.000~5.000.000won 308 45.6
≤2.000.000 won 278 41.2
Religion Christian 175 25.9
Catholic 69 10.2
Buddhist 196 29.0
No religion 231 34.2
Other 4 0.6
Cancer type Gastric 191 28.3
Colorectal 341 50.5
Esophagus 25 3.7
Small intestinal 10 1.5
Hepatobiliary 57 8.4
Pancreatic 51 7.6
Disease status Neoadjuvant or adjuvant 250 37.0
Palliative ≤ first-line 257 38.1
Palliative ≥ second-line 168 24.9




*1000 won is equivalent to one dollar.










<2 hour 4.3 0.919 5.0 0.976
≥2 hour 4.2 5.0
Place of
residence








≤ Middle school 3.2 <0.001 4.6 0.286
High school 4.3 5.0
≥ University 5.0 5.2





≥5.000.000 won 5.0 0.001 5.4 0.310
2.000.000~5.000.000won 4.4 5.0
≤2.000.000 won 3.8 4.8
Religion Christian 4.2 0.552 5.4 0.078
Catholic 4.6 4.4
Buddhist 4.1 5.2
No religion 4.3 4.7
Other 6.5 5.0
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prior exposure to clinical trials.
Awareness of clinical trials
The mean score responses to the question ‘On a scale of
0 to 10, how would you rate your understanding of can-
cer clinical trials?’ was 4.25 ± 2.5 and nearly half of theparticipants (47.9%) selected a value of 5. Table 2 shows
the relationship between awareness of clinical trials and
patient baseline characteristics. A higher educational de-
gree (p<0.001), being married (p=0.004), and higher eco-
nomic status (p=0.001) were associated with a higher
rate of awareness of clinical trials, whereas sex, travel
distance from hospital, residing province in Korea, and
type of religion were not significantly associated with
clinical trial awareness.
Cancer clinical trial understanding
Cancer clinical trial understanding was measured using a
revised Index of Clinical Trial Understanding (ICTU) [17].
When asked about their knowledge of a control group
(Q#10, Table 3), more than 50% of patients (361 of 695)
were aware that a randomized clinical trial was the most
appropriate method to prove the efficacy of a new cancer
drug. More than 80% of patients (545 of 675) agreed (VAS
score > 5) that a cancer clinical trial tested a new drug by
randomizing patients to novel treatment vs. placebo
(Q#14, mean VAS = 6.1 ± 3.1). Nevertheless, when
Table 3 Cancer clinical trial understanding
Question items answers N %
Q#10 Which method do you think would be more effective
in determining the effectiveness of the new drug?
1. Give the new drug to 1000 newly diagnosed cancer patients. 100 14.8
2. Give the new drug to 500 newly diagnosed cancer patients
and give the currently used drug to 500 other newly diagnosed
patients and see which group improves the most.
361 53.5
3. Not sure 214 31.7
Q#11 Randomization 1. Patients should be allowed to select the test group that they
want.
214 31.7
2. Patients need to be assigned to a test group randomly to
make the test accurate.
167 24.7
3. It doesn’t make any difference; either approach will work. 106 15.7
4. Not sure 188 27.9
Q#12 If a doctor were to tell you that patients in a clinical
trial were to be assigned to the new therapy and the
standardtherapy randomly, do you understand randomly
to mean that patients would be assigned by:*
1. The severity of their disease. 235 33.0
2. An independent factor such as the two last digits of a
patient’s telephone number.∗
38 5.3
3. The kind of health insurance that they have. 14 2.0
4. The doctor depending on which group needs more
participants.
311 43.7
5. I am not sure what “randomly” means. 114 16.0
Q#13 If a doctor were to tell you that patients in a clinical
trial were to be assigned to the new therapy and the
standard therapy randomly, do you understand standard
therapy to mean:*
1. An average cancer therapy, not the best and not the worst. 106 15.0
2. The best available therapy for that particular cancer. 317 44.9
3. A placebo or sugar pill with no medical value. 5 0.7
4. An experimental therapy involving a new drug for cancer. 79 11.2
5. I am not sure what “standard therapy” means. 199 28.2
*Multiple selections were allowed.
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214 of 695 patients (31.7%) answered that a treatment
group can be selected based on the patient’s preference in
a randomized trial. Each respondent was subsequently
asked about the meaning of random assignment. Approxi-
mately 80% of the patients answered that they will be ran-
domly assigned according to the severity of their disease
or by a physician’s decision. When asked about their
knowledge of standard therapy, 45% of patients (317 of
675) understood the meaning of standard treatment to be
the best available therapy for that particular cancer and
15% (106 of 675) regarded standard treatment as an aver-
age cancer therapy. Knowledge of placebo was tested
using a VAS score (0, completely disagree to 10, com-
pletely agree). Item Q#14 on the questionnaire asked how
much participants agreed with the following statement:
“When new cancer drugs are tested, half of the subjects
always receive a placebo instead of the new medicine.”
Item Q#15 provided a measure of the general understand-
ing of the purpose of a clinical trial and asked how much
participants agreed with the following statement: “Clinical
trials are essential to advancing medical science and im-
proving the standard of care.” In general, cancer patients
were well aware of the necessity and purpose of cancer
clinical trials with a mean VAS score of 8.1 ± 2.5. The
most frequent source for obtaining information aboutclinical trials was a physician (n=391, 52%) followed by
mass media (n=273, 36.6%), other patients (n=52, 6.9%),
and the internet (n=25, 3.3%).
Participation in clinical trials
The VAS score evaluation of the willingness to partici-
pate in clinical trials produced a mean score of 5.0 ± 3.1.
The total score had an even distribution from 0 to 10
and 256 patients (37.9%) selected 5 as the VAS score.
Table 2 shows the relationship between willingness to
participate in clinical trials and patient characteristics at
baseline. Men were more likely to participate in clinical
trials than women (p=0.001). Importantly, there was a
discrepancy between awareness and participation in clin-
ical trials. Patients with a higher level of education that
were married and had a higher income had a better
understanding of clinical trials. However, the under-
standing of clinical trials did not directly translate into
willingness to participate. Willingness was not affected
by level of education (p=0.286) or economic status
(p=0.310). Of note, patients who obtained their informa-
tion from physicians were more likely to participate in
clinical trials (p<0.001), whereas patients who acquired
information from mass media were less likely to partici-
pate (Table 4, p=0.027). The most influential person
involved in the decision to participate in clinical trials
Table 4 Willingness to participate in a clinical trial
Question Answers N(%) Participation in a clinical trial p-value
Source of information about clinical trials* Physician 391(52.0) 5.4 <0.001
Mass media 273(36.6) 4.7 0.027
Other patients 52(6.9) 4.8 0.696
Internet 25(3.3) 5.3 0.642
Other 11(1.5) 3.7 0.195
Prior participation to clinical trials Yes 127(18.8) 6.8 <0.001
No 548(81.2) 4.6
The decision-making person for clinical trial enrollment* Self 473(62.4) 5.1 0.298
Husband, wife 61(8.0) 5.5 0.187
Children 28(3.7) 4.1 0.150
Parents 1(0.1) 5.0 0.968
Family council 183(24.1) 4.8 0.345
Other 12(1.6) 6.0 0.269
Most influential factor for clinical trial participation Exposure to a new drug 142(21.0) 6.1 <0.001
Financial benefit 50(7.4) 5.3
Contribution to medicine 119(17.6) 5.7
Physician’s recommendation 181(26.8) 4.4
No other treatment option 178(26.4) 4.1
Other reasons 5(0.7) 7.6
Most influential factor for refusal to participate Negative perception of clinical trials 193(28.6) 4.5 0.035
Unconfirmed treatment 320(47.4) 5.2
Frequent hospital visits 53(7.9) 5.8
Prefers standard treatment 101(15.1) 4.9
Other reasons 8(1.2) 5.8
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by ”family” (n=183, 24.1%). A common reason for cancer
trial participation was physician recommendation
(n=181, 26.8%) and no other treatment options (n=178,
26.4%). Nevertheless, the patients who selected these two
answers showed a lower level of willingness to participate.
Conversely, patients who provided exposure to a new drug
as the most influential factor for participation demon-
strated the highest likelihood of clinical trial participation
(6.141, p<0.001). The most important reason for refusal to
participate was unconfirmed treatment (n=320, 47.4%)
followed by negative perception of clinical trials per se
(p=0.035). Patients with a negative perception of clinical
trials showed the lowest willingness to participate.Comparison of patients with and without experience of
clinical trials
Among the 675 patients, 127 (18.8%) had prior experience
of cancer clinical trial participation (Table 5). Patients with
previous experience in clinical trials were more willing to
participate in clinical trials compared to patients without
previous experience in clinical trials (p<0.001).For the question “What is the most important reason
for participating if you decide to join a clinical trial?”,
“using a new drug” (n=39, 30.7%) ranked first for
patients with experience of clinical trials, whereas “for
nothing other than treatment” (n=159, 29.0%) was the
leading cause in patients without experience of clinical
trials. For the question “What is most important reason
for not participating if you decide not to join a clinical
trial?”, “the anxiety of unverified treatment” (51.2%,
46.5%, respectively) was the most common answer in
both groups. The second most common answer was “ob-
jection to clinical trials themselves” (22.0% vs. 30.1%)
and the difference between the two groups was statisti-
cally significant (p=0.019).Discussion
Korea has been facing a rapid increase in cancer inci-
dence [18], and the volume of cancer clinical trials has
increased accordingly. Progress in cancer treatment can
only come from investigations of novel therapies and
treatment strategies performed in the setting of well
conducted clinical trials [1]. Because participation in
Table 5 Prior exposure to clinical trials and willingness to participate







Most influential factor for clinical trial participation Using a new drug 39(30.7) 103(18.8) 0.001
Economic benefit 8(6.3) 42(7.7)
Contribute to medical development 21(16.5) 98(17.9)
Physician’s recommendation 37(29.1) 144(26.3)
No other treatment option 19(15.0) 159(29.0)
Other 3(2.4) 2(0.4)
Most influential factor for refusal to participate Negative perception of clinical trials 28(22.0) 165(30.1) 0.019
Unconfirmed treatment 65(51.2) 255(46.5)
Frequent hospital visits 8(6.3) 45(8.2)
Prefers standard treatment 21(16.5) 80(14.6)
Other reasons 5(4.9) 3(0.6)
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higher survival rate [19], clinical trials have become an
important facet of oncology, and the need for clinical
studies continues to grow. Our study has shown that
willingness to participate in clinical trials is intermediate
in Asian patients with GI and hepatobiliary-pancreatic
cancer. The mean VAS score of 5.0, the median score of
5, and evenly distributed total score from 0 to 10 showed
some differences from results of prior studies performed
in Western countries, where the majority of patients
with cancer were willing to consider participating in
clinical trials [14,17,20,21].
Overall, Korean cancer patients understood the need
for two treatment arms to prove drug efficacy (N=361,
53.5%), which is considerably higher than in the Western
studies (33% of the public and 37% of cancer survivors)
[17]. Nevertheless, our study indicated that more than
70% of patients did not possess accurate knowledge of
randomized trials: 31.7% (n=214) of patients thought
they could choose the study treatment arm in a rando-
mized trial and 43.7% (n=311) answered that a doctor’s
decision is the most influential factor for randomization.
Only 5.3% of patients understood the exact meaning of
randomization, which is substantially lower than the per-
centage reported in Western studies (63% of the public
and 67% of cancer survivors). Furthermore, less than half
of our cancer patients were aware that standard treat-
ment referred to the best current practice for a specific
disease while 66% of the Western cancer patients were
aware of the meaning of standard treatment in cancer
care [17]. Taken together, although a higher rate of can-
cer patients were aware of randomized trials than in the
West, a much smaller percentage of cancer patients had
precise knowledge of the randomization process or of
assignment of a treatment arm in randomized trials.
Based on our results, more detailed explanations on therandomization procedure should be provided to patients
at our hospital, since there was a high discordance rate
between the awareness and the understanding of a ran-
domized clinical trial.
Interestingly, a higher level of awareness did not al-
ways result in increased willingness to participate in
clinical trials, in contrast to the findings of previous
Western studies [4,7,21-24]. This might represent one of
the peculiar features of Asian cancer patients that should
be confirmed in another cancer patient cohort.
As shown in Tables 4 and 5, the most influential factor
for willingness to participate in clinical trials was ‘physi-
cian’s recommendation’ (26.8%) and this was similar to
Western findings which showed the strongest predictor
of expected enrollment of clinical trials was encourage-
ment by the physician [17]. In contrast to a common be-
lief, however, the main decision-making person for
clinical trial participation in Korea was the patient (473
of 675, 62.4%).
In this study cohort, a total of 127 participants (18.8%)
had a prior history of clinical trial enrollment. This
population represented a unique patient population with
different behavior from the remaining patients. For in-
stance, there was high concordance between clinical trial
awareness and willingness to participate (p<0.001). In
addition, the most common motivation for clinical trial
participation was exposure to a new drug (30.7% vs.
18.8%; prior experience vs. no experience group, Table 5).
In addition, the negative perception of clinical trials was
significantly lower in patients (n=28 of 127, 22%) with
prior experience when compared with no experience
(n=165 of 548, 30.1%).
We note that our study has some limitations. First, an
inherent selection bias may exist owing to the fact that
the study was conducted in only one tertiary academic
hospital. Second, another selection bias was introduced
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were asked to join this survey and only 67.5% of patients
completed the questionnaire. In addition, the percentage
of clinical trial participants may have influenced and
altered the results of this survey. The rate of clinical trial
participants for GI and hepatobiliary-pancreatic cancer
at Samsung Medical Center ranges from 10 – 20% at all
times which is in accordance with the proportion of clin-
ical trial participants in this study (18.8%). Hence, the
proportion of participants was not biased or misrepre-
sented in this study.
Conclusions
In conclusion, our study involved a large patient cohort
and we used VAS scores to inquire about the awareness
of, and willingness to participate in, clinical trials in
Asian cancer patients. Based on this study, we plan to
do a follow-up study in five or ten years to analyze the
evolving trend in perception of clinical trials in Korean
cancer patients. Through this survey study, we estab-
lished and defined unique features of our patients.
Understanding a cancer patient’s perception, willingness
to participate, and influential factors underlying deci-
sions could facilitate patient recruitment for clinical
trials in Asia.
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